SuperworthKiniksa Pharmaceuticals International KNSA
- Market cap
- $6B
- PE
- 79.1×
- 3y median 85.3×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 7.1×
- EV/EBIT
- 54.6×
- Revenue, 12 months
- $840.8M
- +59% on a year ago
- Net margin
- 9.6%
- Free cash flow yield
- 3.1%
Kiniksa Pharmaceuticals International trades at 79.1× trailing earnings, near its ten-year median. Revenue was $840.8M over the last twelve months, up 59% on a year earlier with a 10% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $67M−32% | $83.4M+35% | $79.9M+65% | $108.6M+52% | $112.2M+67% | $122.5M+47% | $137.8M+73% | $156.8M+44% | $180.9M+61% | $202.1M+65% | $214.3M+56% | $243.6M+55% | |
| Cost of revenue | $9.1M+31% | $66.1M+115% | $10.6M+50% | $12.3M+60% | $20.1M+121% | $17.9M−73% | $17.9M+69% | $18.6M+51% | $20.3M+1% | $20.9M+17% | $20.8M+16% | $23.6M+27% |
| Gross profit | $58M−37% | $17.3M−44% | $69.3M+68% | $96.3M+51% | $92.1M+59% | $104.6M+505% | $119.9M+73% | $138.2M+44% | $160.6M+74% | $181.2M+73% | $193.5M+61% | $220M+59% |
| R&D | $17.1M+4% | $20.1M+39% | $26.3M+74% | $24M+1% | $26.1M+52% | $35.2M+76% | $19.3M−27% | $18.8M−22% | $24.2M−7% | $34.6M−2% | $27.5M+42% | $40.9M+118% |
| SG&A | $34.5M+40% | $36.7M+35% | $38.7M+33% | $42.4M+45% | $46.4M+35% | $40.5M+10% | $43.5M+13% | $46.9M+11% | $49.1M+6% | $56.8M+40% | $61.2M+41% | $63.9M+36% |
| −$10.9M | $81K−99% | −$16.5M+48% | −$117K−96% | −$9.7M−12% | −$19.3M | $13.3M | $20.2M | $24M | $19.8M | $29.3M+121% | $27.2M+35% | |
| Pre-tax income | −$8.5M | $2.5M−64% | −$14.3M+53% | $2.3M | −$7.2M−15% | −$17M | $15.6M | $22.9M+893% | $27.2M | $23.3M | $32.7M+110% | $31.1M+36% |
| $5.4M | −$22.8M | $3.4M+18% | $6.2M | $5.5M+3% | −$8.1M−65% | $7M+105% | $5M−19% | $8.7M+59% | $9.1M | $10.1M+44% | $5.7M+13% | |
| Net income | −$13.9M | $25.2M+466% | −$17.7M+44% | −$3.9M | −$12.7M−8% | −$8.9M | $8.5M | $17.8M | $18.4M | $14.2M | $22.6M+165% | $25.4M+43% |
| −$0.20 | $0.35+483% | −$0.25+39% | −$0.06 | −$0.18−10% | −$0.12 | $0.11 | $0.23 | $0.23 | $0.17 | $0.27+146% | $0.30+30% | |
| 70.2M−1% | 72.2M+2% | 70.6M+1% | 71M−1% | 71.7M+2% | 72.3M+0% | 76.1M+8% | 77.9M+10% | 80M+12% | 81.8M+13% | 82.4M+8% | 83.4M+7% |
Gross profit: 21 periods, Q2 FY21 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY17: 6 months less the 3 months printed beside them.
SG&A: Q1 FY17: 6 months less the 3 months printed beside them.
Operating income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Income tax: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Net income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
EPS, diluted: 10 periods, Q1 FY17 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY17: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY17 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Kiniksa Pharmaceuticals International's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KNSAKiniksa Pharmaceuticals International | $6B | 79.1× | 85.3× | 7.1× | +59% | 9.6% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.3× | 37.7× | 20.8× | +55% | 67.9% | |
| AMRXAmneal Pharmaceuticals | $6.5B | 41.6× | 51.5× | 2.1× | +9% | 5.0% | |
| ALKSAlkermes plc. | $7.3B | 115× | 16.0× | 4.4× | +11% | 4.0% | |
| TGTXTG Therapeutics | $8.3B | 19.8× | 19.4× | 10.4× | +76% | 55.2% | |
| INDVIndivior Pharmaceuticals | $4.1B | 12.4× | 20.1× | 3.1× | +13% | 26.7% | |
| PTGXProtagonist Therapeutics | $9B | 134× | 58.3× | 31.8× | +35% | 29.4% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| CORTCorcept Therapeutics | $9.3B | 204× | 28.3× | 11.2× | +16% | 6.6% | |
| LQDALiquidia | $3.8B | 30.7× | 53.6× | 8.5× | n/m | 30.7% | |
| OGNOrganon | $3.6B | 17.9× | 5.9× | 0.6× | −2% | 3.4% | |
| Peer median | $6.3B | 36.9× | 33.0× | 8.5× | +16% | 16.6% |
More on Kiniksa Pharmaceuticals International
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .